Company Filing History:
Years Active: 2015
Title: Sabine Muenkel: Innovator in Tumor Necrosis Factor Research
Introduction
Sabine Muenkel is a prominent inventor based in Gaertringen, Germany. She has made significant contributions to the field of biomedical research, particularly in the development of selective antagonists for the human tumor necrosis factor type 1 receptor (huTNFR1). Her work has the potential to impact the treatment of various disorders related to this receptor.
Latest Patents
Muenkel holds a patent for huTNFR1 selective antagonists. The present invention relates to a ligand that specifically binds to huTNFR1. This ligand includes one or more amino acid sequences of human origin that are capable of reducing the immunogenic response in humans. Additionally, it contains one or more amino acid sequences that selectively bind to huTNFR1. The invention also encompasses a nucleic acid sequence encoding the ligand and a pharmaceutical composition for treating disorders associated with huTNFR1. She has 1 patent to her name.
Career Highlights
Muenkel is affiliated with the University of Stuttgart, where she continues her research and development efforts. Her work is characterized by a commitment to advancing medical science and improving therapeutic options for patients.
Collaborations
Throughout her career, Muenkel has collaborated with notable colleagues, including Klaus Pfizenmaier and Peter Scheurich. These collaborations have further enriched her research and contributed to the advancement of her inventions.
Conclusion
Sabine Muenkel is a dedicated inventor whose work on huTNFR1 selective antagonists showcases her innovative spirit and commitment to improving healthcare. Her contributions to the field of biomedical research are noteworthy and have the potential to lead to significant advancements in treatment options.